Description
Inqovi Uses:
Inqovi Tablet is a combination of decitabine (a nucleoside metabolic inhibitor), and cedazuridine (a cytidine deaminase inhibitor), used to treat adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1/2, and high-risk International Prognostic Scoring System groups.
Dosage: The recommended dosage of Inqovi is 1 tablet (containing 35 mg decitabine and 100 mg cedazuridine) administered orally once a day on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until the disease is progressive or unacceptable toxicity occur. A complete or partial response may take longer than 4 cycles.
Take inqovi 35 mg-100 mg tablets at the same time each day. Swallow tablets whole. Do not cut/crush/chew your tablets. Avoid consuming food 2 hours before and 2 hours following each dose. In case the patient misses a dose within 12 hours of the time it is usually taken, patients are advised to take the missed dose quickly and then to resume the normal daily dosing schedule. The dosing period can be extended by one day for every missed dose to complete 5 daily doses for each cycle. Avoid taking an additional dose in case vomiting occurs after the dose of inqovi but continue with the next scheduled dose.
Side Effects: The most commonly reported inqovi side effects (incidence ≥20%) include:
- Fatigue
- Constipation
- Hemorrhage
- Myalgia
- Mucositis
- Arthralgia
- Nausea
- Dyspnea
- Diarrhea
- Rash
- Dizziness
- Febrile neutropenia
- Edema
- Headache
- Cough
- Decreased appetite
- Upper respiratory tract infection
- Pneumonia
- Transaminase increased
Warnings and Precautions:
- Complete blood cell counts should be obtained prior to initiation of therapy with inqovi tablets, prior to each cycle, and as clinically indicated to evaluate response and toxicity.
- All the respective women should not breastfeed during therapy with decitabine/cedazuridine dosage and for two weeks after the last dose.
- All the females of reproductive age or potential should inform their health specialist of a known or suspected pregnancy.
- Patients should take decitabine plus cedazuridine at around the same time each day on an empty stomach. Do not eat for at least two hours before and two hours after taking the medication.
